Alternatives to risk-reducing surgery for ovarian cancer

Annals of Oncology

Volumn 24, Issue SUPPL.B, 2013, Pages

  Gadducci, A ^a   Sergiampietri, C ^a   Tana, R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

BRCA; CA125; Ovarian carcinoma; Screening; Trans vaginal ultrasound; Tumor marker

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; FENRETINIDE; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; ORAL CONTRACEPTIVE AGENT; OSTEOPONTIN; PLACEBO; PROLACTIN; RETINOID; SOMATOMEDIN B;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; GENE MUTATION; GENETIC RISK; HUMAN; INTRADUCTAL CARCINOMA; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; RETROPERITONEAL CANCER; RISK REDUCTION; SALPINGECTOMY; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; UTERINE TUBE CARCINOMA;

BRCA; CA125, OVARIAN CARCINOMA; SCREENING; TRANS-VAGINAL ULTRASOUND; TUMOR MARKER;

BRCA1 PROTEIN; BRCA2 PROTEIN; CA-125 ANTIGEN; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LEPTIN; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; OSTEOPONTIN; OVARIAN NEOPLASMS; OVARIECTOMY; PROLACTIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84886294331     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt311     Document Type: Article

References (86)

1. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol 2009; 472: 413-437.
2. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23: 276-292.
3. Tailor A, Bourne TH, Campbell S et al. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003; 21: 378-385.
4. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. breast cancer linkage consortium. Am J Hum Genet 1995; 56: 265-271.
5. King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646.
6. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
7. Søgaard M, Kjaer SK, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand 2006; 85: 93-105.
8. Chen S, Iversen ES, Friebel T et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. Clin Oncol 2006; 24: 863-871.
9. Olivier RI, van Beurden M, Lubsen MA et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004; 90: 1492-1497.
10. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475-1479.
11. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
12. Kauff ND, Satagopan JM, Robson ME et al. Risk reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.
13. Rutter JL, Wacholder S, Chetrit A et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 2003; 95: 1072-1078.
14. Kramer JL, Velazquez IA, Chen BE et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J ClinOncol 2005; 23: 8629-8635.
15. Eisen A, Lubinski J, Klijn J et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international casecontrol study. J ClinOncol 2005; 23: 7491-7496.
16. Domchek SM, Friebel TM, Neuhausen SL et al. Mortality after bilateral salpingooophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006; 7: 223-229.
17. Finch A, Beiner M, Lubinski J et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296: 185-192.
18. Chang-Claude J, Andrieu N, Rookus M et al. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2007; 16: 740-746.
19. Kauff ND, Domchek SM, Friebel TM et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 associated breast and gynecologic cancer: a multi-center, prospective study. J Clin Oncol 2008; 26: 1331-1337.
20. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-87.
21. Bacha OM, Gregoire J, Grondin K et al. Effectiveness of risk-reducing salpingooophorectomy in preventing ovarian cancer in a high-risk French Canadian population. Int J Gynecol Cancer 2012; 22: 974-978.
22. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-456.
23. Shaw PA, Rouzbahman M, Pizer ES et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009; 22: 1133-1138.
24. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
25. Folkins AK, Jarboe EA, Saleemuddin A et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168-173.
26. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518.
27. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-931.
28. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
29. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol 2009; 4: 287-313.
30. Salani R, Kurman RJ, Giuntoli R, II et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 2008; 18: 487-491.
31. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819.
32. Bowell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010; 10: 803-808.
33. Gadducci A, Guerrieri ME, Genazzani AR. New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications. Gynecol Endocrinol 2012; 28: 582-586.
34. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305: 2295-2303.
35. Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10: 327-340.
36. Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995; 76:(Suppl. 10): 2004-2010.
37. Skates SJ, Menon U, MacDonald N et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21(Suppl. 10): 206s-210s.
38. Menon U, Kalsi J, Jacobs I. The UKCTOCS experience-reasons for hope? Int J Gynecol Cancer 2012; 22: S18-S20.
39. Pinsky PF, Zhu C, Skates SJ et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer 2013; 132: 2127-2133.
40. Laframboise S, Nedelcu R, Murphy J et al. Use of CA-125 and ultrasound in highrisk women. Int J Gynecol Cancer 2002; 12: 86-91.
41. Liede A, Karlan BY, Baldwin RL et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 2002; 20: 1570-1577.
42. Scheuer L, Kauff N, Robson M et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20: 1260-1268.
43. Fries MH, Hailey BJ, Flanagan J et al. Outcome of five years of accelerated surveillance in patients at high risk for inherited breast/ovarian cancer: report of a phase II trial. Mil Med 2004; 169: 411-416.
44. Kauff ND, Hurley KE, Hensley ML et al. Ovariancarcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. Cancer 2005; 104: 314-320.
45. Meeuwissen PA, Seynaeve C, Brekelmans CT et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005; 97: 476-482.
46. Gaarenstroom KN, van der Hiel B, Tollenaar RA et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006; 16(Suppl. 1): 54-59.
47. Vasen HF, Tesfay E, Boonstra H et al. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 2005; 41: 549-554.
48. Hermsen BB, Olivier RI, Verheijen RH et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007; 96: 1335-1342.
49. Madalinska JB, Hollenstein J, Bleiker E et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J ClinOncol 2005; 23: 6890-6898.
50. Oei AL, Massuger LF, Bulten J et al. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 2006; 94: 814-819.
51. Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-1679.
52. Zhang Z, Bast RC, Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-5890.
53. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3: 355-366.
54. Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 7677-7682.
55. Visintin I, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14: 1065-1072.
56. Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvicmass. Gynecol Oncol 2008; 108: 402-408.
57. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40-46.
58. Clarke CH, Yip C, Badgwell D et al. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 2011; 122: 548-553.
59. Høgdall C, Fung ET, Christensen IJ et al. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol 2011; 123: 308-313.
60. Moore LE, Pfeiffer RM, Zhang Z et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2012; 118: 91-100.
61. Tworoger SS, Eliassen AH, Rosner B et al. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004; 64: 6814-6819.
62. Singer CF, Mogg M, Koestler Wet al. Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. Clin Cancer Res 2004; 10: 4003-4009.
63. Popovic V, Casanueva FF. Leptin, nutrition and reproduction: new insights. Hormones 2002; 1: 204-217.
64. Bachelot A, Binart N. Corpus luteum development: lessons from genetic models in mice. Curr Top DevBiol 2005; 68: 49-84.
65. Grosdemouge I, Bachelot A, Lucas A et al. Effects of deletion of the prolactin receptor on ovarian gene expression. Reprod Biol Endocrinol 2003; 1: 12.
66. Giudice LC. Insulin-like growth factor family in Graafian follicle development and function. J Soc Gynecol Investig 2001; 8: S26-S29.
67. La Vecchia C. Oral contraceptives and ovarian cancer: an update, 1998-2004. Eur J Cancer Prev 2006; 15: 117-124.
68. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335: 651.
69. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008; 371: 303-314.
70. Cameron S. Contraception and gynaecological care. Best Pract Res Clin Obstet Gynaecol 2009; 23: 211-220.
71. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339: 424-428.
72. Whittemore AS, Balise RR, Pharoah PD et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004; 491: 1911-1915.
73. McGuire V, Felberg A, Mills M et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 2004; 160: 613-618.
74. McLaughlin JR, Risch HA, Lubinski J et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8: 26-34.
75. Antoniou AC, Rookus M, Andrieu N et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009; 18: 601-610.
76. Cibula D, Zikan M, Dusek L et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 2011; 11: 1197-1207.
77. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41: 41-55.
78. Mehta RG, Moon RC, Hawthorne M et al. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer 1991; 27: 138-141.
79. Cazzaniga M, Varricchio C, Montefrancesco C et al. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? J Biomed Biotechnol 2012; 2012: 172897.
80. Veronesi U, De Palo G, Marubini E et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999; 91: 1847-1856.
81. Veronesi U, Mariani L, Decensi A et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006; 17: 1065-1071.
82. Delia D, Aiello A, Meroni L et al. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997; 18: 943-948.
83. Maurer BJ, Melton L, Billups C et al. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000; 92: 1897-1909.
84. Appierto V, Tiberio P, Villani MG et al. PLAB Induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis 2009; 30: 824-831.
85. Tiberio P, Cavadini E, Callari M et al. AF1q: a novel mediator of basal and 4-HPRinduced apoptosis in ovarian cancer cells. PLoS One 2012; 7: e39968.
86. Greene MH, Piedmonte M, Alberts D et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a gynecologic oncology. Cancer Epidemiol Biomarkers Prev 2008; 17: 594-604.